drugset / Trial / NCT06091826

Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO)

NCT06091826 ↗

Phase 2 Completed 34 enrolled NFL Biosciences SAS
RandomizedCrossoverQuadruple-blindTreatment

Summary

PRECESTO is a randomized, double-blind, cross-over trial on 34 smokers who do not want to stop smoking and get high satisfaction from smoking. The primary objective is to assess efficacy of NFL-101 in reducing the positive reinforcing properties of cigarettes compared to placebo measured by the modified Cigarette Evaluation Questionnaire (mCEQ) "Smoking Satisfaction" (items 1, 2, and 12) subscale.

Timeline

Start
2023-02-21
Primary completion
2023-09-15
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NFL-101 Protein / enzyme biologic 100 ug Subcutaneous

Indications